PMID- 25363560
OWN - NLM
STAT- MEDLINE
DCOM- 20151117
LR  - 20201222
IS  - 1600-0625 (Electronic)
IS  - 0906-6705 (Linking)
VI  - 24
IP  - 1
DP  - 2015 Jan
TI  - Effective induction of melanoma-antigen-specific CD8+ T cells via Vgamma9gammadeltaT cell 
      expansion by CD56(high+) Interferon-alpha-induced dendritic cells.
PG  - 35-41
LID - 10.1111/exd.12581 [doi]
AB  - Dendritic cells (DCs) can be differentiated from CD14+ monocytes in the presence 
      of interferon-alpha (IFNalpha) and granulocyte/macrophage-colony stimulating factor 
      (GM-CSF) in vitro and are known as IFN-DCs. Circulating blood CD56+ cells 
      expressing high levels of CD14, HLA-DR and CD86 have been shown to spontaneously 
      differentiate into DC-like cells in vitro after their isolation from blood. We 
      show here that IFN-DCs expressing high levels of CD56 (hereafter, CD56(high+) 
      IFN-DCs) can be differentiated in vitro from monocytes obtained as adherent cells 
      from healthy donors and patients with metastatic melanoma. These cells expressed 
      high levels of CD14, HLA-DR and CD86 and possessed many pseudopodia. These 
      CD56(high+) IFN-DCs may be an in vitro counterpart of the circulating CD56+ CD14+ 
      CD86+ HLA-DR+ cells in blood. Conventional mature DCs differentiated from 
      monocytes as adherent cells in the presence of GM-CSF, IL-4 and TNF-alpha (hereafter, 
      mIL-4DCs) did not express CD56 or CD14. In contrast to mIL-4DCs, the CD56(high+) 
      IFN-DCs exhibited a stronger capacity to stimulate autologous CD56+ Vgamma9gammadeltaT cells 
      highly producing IFNgamma in the presence of zoledronate and IL-2. The CD56(high+) 
      IFN-DCs possessing HLA-A*0201 effectively induced Mart-1-modified melanoma 
      peptide (A27L)-specific CD8+ T cells through preferential expansion of CD56+ 
      Vgamma9gammadeltaT cells in the presence of A27L, zoledronate and IL-2. Vaccination with 
      CD56(high+) IFN-DCs copulsed with tumor antigens and zoledronate may orchestrate 
      the induction of various CD56+ immune cells possessing high effector functions, 
      resulting in strong immunological responses against tumor cells. This study may 
      be relevant to the design of future clinical trials of CD56(high+) IFN-DCs-based 
      immunotherapies for patients with melanoma.
CI  - (c) 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Nieda, Mie
AU  - Nieda M
AD  - Biotherapy Institute of Japan, Koutou-ku, Tokyo, Japan.
FAU - Terunuma, Hiroshi
AU  - Terunuma H
FAU - Eiraku, Yuuta
AU  - Eiraku Y
FAU - Deng, Xuewen
AU  - Deng X
FAU - Nicol, Andrew J
AU  - Nicol AJ
LA  - eng
PT  - Journal Article
DEP - 20141208
PL  - Denmark
TA  - Exp Dermatol
JT  - Experimental dermatology
JID - 9301549
RN  - 0 (CD56 Antigen)
RN  - 0 (Diphosphonates)
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Imidazoles)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukin-2)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Antigen, T-Cell, gamma-delta)
RN  - 0 (T-cell receptor Vgamma9, human)
RN  - 6XC1PAD3KF (Zoledronic Acid)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - CD56 Antigen/*metabolism
MH  - CD8-Positive T-Lymphocytes/*cytology
MH  - Dendritic Cells/*metabolism
MH  - Diphosphonates/chemistry
MH  - Flow Cytometry
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/metabolism
MH  - HLA-A2 Antigen/metabolism
MH  - Humans
MH  - Imidazoles/chemistry
MH  - Immunotherapy
MH  - Interferon-alpha/*metabolism
MH  - Interleukin-2/metabolism
MH  - Leukocytes, Mononuclear/cytology
MH  - Lipopolysaccharide Receptors/metabolism
MH  - Lymphocytes/cytology
MH  - Melanoma/immunology/*metabolism/therapy
MH  - Monocytes/cytology
MH  - Peptides/metabolism
MH  - Phenotype
MH  - Receptors, Antigen, T-Cell, gamma-delta/*immunology
MH  - Skin Neoplasms/immunology/metabolism/therapy
MH  - Zoledronic Acid
OTO - NOTNLM
OT  - IFN alpha
OT  - Vgamma9gammadeltaT
OT  - immunotherapy
OT  - melanoma-antigen-specific CD8+ T
OT  - zoledronate
EDAT- 2014/11/05 06:00
MHDA- 2015/11/18 06:00
CRDT- 2014/11/04 06:00
PHST- 2014/10/28 00:00 [accepted]
PHST- 2014/11/04 06:00 [entrez]
PHST- 2014/11/05 06:00 [pubmed]
PHST- 2015/11/18 06:00 [medline]
AID - 10.1111/exd.12581 [doi]
PST - ppublish
SO  - Exp Dermatol. 2015 Jan;24(1):35-41. doi: 10.1111/exd.12581. Epub 2014 Dec 8.